Betahistine

Betahistine
Clinical data
Trade names	Serc, others
AHFS/Drugs.com	International Drug Names
Pregnancy; category	C (risk not ruled out);
Routes of; administration	By mouth, intranasal
ATC code	N07CA01 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	~100%
Protein binding	<5%
Metabolism	Liver
Metabolites	• 2-(2-Aminoethyl)pyridine; • 2-Pyridylacetic acid
Onset of action	<1 hour (peak)
Elimination half-life	3.5 hours
Excretion	Urine: 91%
Identifiers
	IUPAC name methyl[2‐(pyridin‐2‐yl)ethyl]amine;
CAS Number	5638-76-6 ;
PubChem CID	2366;
DrugBank	DB06698 ;
ChemSpider	2276 ;
UNII	X32KK4201D;
KEGG	D07522 ;
ChEBI	CHEBI:35677 ;
ChEMBL	ChEMBL24441 ;
CompTox Dashboard (EPA)	DTXSID3022665 ;
ECHA InfoCard	100.024.625
Chemical and physical data
Formula	C8H12N2
Molar mass	136.198 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1ccccc1CCNC;
	InChI InChI=1S/C8H12N2/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H3 ; Key:UUQMNUMQCIQDMZ-UHFFFAOYSA-N ;
	(verify)

Betahistine, sold under the brand name Serc among others, is an anti-vertigo medication. It is commonly prescribed for balance disorders or to alleviate vertigo symptoms. It was first registered in Europe in 1970 for the treatment of Ménière's disease, but current evidence does not support its efficacy in treating it.^[4]^[5]

^ ^a ^b ^c ^d ^e Dickenson A (2017). Drugs in Neurology. Oxford University Press. pp. 408–409. ISBN 978-0-19-966436-8.
^ White R, Bradnam V (2015). Handbook of Drug Administration via Enteral Feeding Tubes (3rd ed.). Pharmaceutical Press. pp. 125–. ISBN 978-0-85711-162-3.
^ Tiziani AP (2013). Havard's Nursing Guide to Drugs. Elsevier Health Sciences. pp. 1063–. ISBN 978-0-7295-8162-2.
^ James AL, Burton MJ (2001). "Betahistine for Menière's disease or syndrome". The Cochrane Database of Systematic Reviews. 2001 (1): CD001873. doi:10.1002/14651858.CD001873. PMC 6769057. PMID 11279734.
^ Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M (January 2016). "Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)". BMJ. 352: h6816. doi:10.1136/bmj.h6816. PMC 4721211. PMID 26797774.

[Dickenson2017-1] Dickenson A (2017). Drugs in Neurology. Oxford University Press. pp. 408–409. ISBN 978-0-19-966436-8.

[WhiteBradnam2015-2] White R, Bradnam V (2015). Handbook of Drug Administration via Enteral Feeding Tubes (3rd ed.). Pharmaceutical Press. pp. 125–. ISBN 978-0-85711-162-3.

[Tiziani2013-3] Tiziani AP (2013). Havard's Nursing Guide to Drugs. Elsevier Health Sciences. pp. 1063–. ISBN 978-0-7295-8162-2.

[Jam2001-4] James AL, Burton MJ (2001). "Betahistine for Menière's disease or syndrome". The Cochrane Database of Systematic Reviews. 2001 (1): CD001873. doi:10.1002/14651858.CD001873. PMC 6769057. PMID 11279734.

[Adr2016-5] Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M (January 2016). "Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)". BMJ. 352: h6816. doi:10.1136/bmj.h6816. PMC 4721211. PMID 26797774.

[1]

[2]

[3]

[4]

[5]